Clinical Trial Update: Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and immunogenicity of a stabilized CH505 TF HIV envelope trimer vaccine in healthy, HIV-uninfected adults; results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Stabilized CH505 TF chTrimer vaccine (Stabilized CH505 TF HIV envelope trimer)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2026-02-27